6 / 6
Page 32
Der Pharmacia Sinica
ISSN: 0976-8688
Eurosc i con Conference on
Medicinal Chemistry
and Biosimilars
M a r c h 2 5 - 2 6 , 2 0 1 9
B u d a p e s t , H u n g a r y
Medicinal Chemistry & Biosimilars 2019
A
therosclerosis is a chronic disease that is characterized by accumulation
of lipids and oxidized lipids within the intima of the arterial wall. It is
the usual cause of heart attacks, strokes, and peripheral vascular which all
together called cardiovascular disease (CVD). Lowering low density lipoprotein
(LDL) levels in the circulation using statins therapy has become an integral
strategy to reduce CVD risk. However, statins reduce CVD event rates by has a
central role in atherosclerosis inhibition due to its anti-atherogenic properties
such as, reverse cholesterol transport (RCT), antioxidant, anti-inflammatory
and endothelial function improvement. Epidemiological data, animal studies
and clinical trials supports HDL as the next target to reduce CVD risk. However,
some findings have called into question the hypothesis that pharmacological
increase in HDL-cholesterol levels is necessarily promoting reduction of CVD
events. Instead, recent studies indicate that the focus should be on improving
HDL functions (HDL quality), which truly reflect its actual beneficial effects,
rather than increasing HDL-C levels (HDL-C quantity). Our hypothesis is that
natural agents with the potential to alter HDL proteomics and lipidomics can
improve the atheroprotective effects and functions of HDL and may reduce
CVD risk. In our laboratory a promising active compound from an ethanol–
water (70:30%) extract of Nannochloropsis sp. Microalgae was isolated.
The structure of the compound was determined to be lyso-DGTS lipid. Lyso-
DGTS interacts with HDL proteins, enhances paraxonase 1 (PON1), protein
that contribute to many of the atheroprotective effects of HDL and elevate
many of the HDL activities such as, HDL mediated cholesterol efflux from
macrophages, HDL ability to induce nitric oxide release from endothelial cells
and HDL antioxidant and anti-inflammatory properties. Our findings suggest
a beneficial effect of lyso-DGTS on improving HDL quality which may reduce
atherosclerotic risk.
Biography
Soliman Khatib has completed his PhD from the Technion
institute, Natural Science, Chemistry in 1996-2000. He has
completed his BSC from Ben-Gurion University, Natural
Science, Chemistry 1993-1995. Now he is a Researcher in the
laboratory of oxidative stress, Migal-Galilee Research institute
and a Senior Lecturer at Department of Biotechnology, Tel-Hai
academic collage. His research focus on understanding the
relationship between oxidative stress and diseases related to
oxidative stress, identifying volatile organic compounds (VOCs)
as early biomarkers for diseases related to oxidative stress;
Isolation and identification of natural compounds for treating
and preventing diseases related to oxidative stress such as,
atherosclerosis, Parkinson and Alzheimer diseases. He has
published more than 50 papers in reputed journals.
solimankh@migal.org.ilReducing cardiovascular disease (CVD) risk using agents
which elevate PON1 activity and improve HDL quality
Soliman Khatib
MIGAL-Galilee Research Institute, Israel
Soliman Khatib, Der Pharmacia Sinica 2019, Volume:10
DOI: 10.21767/0976-8688-C1-002